Trial Profile

A Retrospective Observational Study to Compare Real-World Glycemic Effectiveness of Dulaglutide (DU) Versus Basal Insulin (BI) in Patients with Type 2 Diabetes (T2D)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 16 Jul 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dulaglutide (Primary) ; Insulin degludec; Insulin detemir; Insulin glargine
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Acronyms DISPEL

16 Jul 2019 New trial record
11 Jun 2019 Results assessing glycemic effectiveness of Dulaglutide (DU) versus Basal Insulin (BI) in patients from this study, were presented at the 79th Annual Scientific Sessions of the American Diabetes Association.
22 May 2019 Results assessing one year economic outcomes from this study (n=523 Dulaglutide:Basal Insulin pairs), were presented at the 24th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com